GNMX targets companies developing genomic sequencing, gene editing, and precision medicine technologies that could transform healthcare from one-size-fits-all treatments to personalized therapies based on individual genetic profiles.
How It Works
The fund invests in pure-play genomics companies like sequencing equipment makers and gene therapy developers, plus larger pharma and tech firms with significant precision medicine divisions. Holdings are weighted by a proprietary scoring system that emphasizes R&D spending, patent portfolios, and clinical pipeline progress rather than market cap.
Key Features
- Captures both established players (Illumina, Thermo Fisher) and emerging biotech disruptors in CRISPR and cell therapy
- More concentrated than broad biotech ETFs, typically holding 30-50 names vs 200+ in sector funds
- Includes non-US companies leading in genomics research, particularly from China and Europe
Risks
- Clinical trial failures can crater individual holdings 50-80% overnight — expect stomach-churning volatility
- Regulatory setbacks or ethical concerns around gene editing could freeze the entire sector for months
- Many holdings burn cash and won't be profitable for years, making them vulnerable in market downturns
Who Should Own This
Best for investors with 10+ year horizons who believe genomics will revolutionize medicine and can handle biotech-level volatility. Works as a 2-5% satellite position for those already overweight traditional healthcare but wanting next-generation exposure. Not suitable for anyone needing stability or income.